{
    "organizations": [],
    "uuid": "0638ae04ff1b733994470f3d5fffdb5be39623ff",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-oncomed-reports-q1-loss-per-share/brief-oncomed-reports-q1-loss-per-share-0-15-idUSASC0A0MX",
    "ord_in_thread": 0,
    "title": "BRIEF-Oncomed Reports Q1 Loss Per Share $0.15",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - OncoMed Pharmaceuticals Inc:\n* ONCOMED ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS\n* Q1 REVENUE $7.8 MILLION VERSUS $6.2 MILLION * CURRENT CASH IS ESTIMATED TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q3 OF 2019\n* ONCOMED PHARMACEUTICALS - ESTIMATES 2018 OPERATING CASH BURN TO BE APPROXIMATELY $55 MILLION, BEFORE CONSIDERING POTENTIAL MILESTONE OR OPT-IN PAYMENTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-09T06:46:00.000+03:00",
    "crawled": "2018-05-09T12:21:11.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "oncomed",
        "pharmaceutical",
        "inc",
        "oncomed",
        "announces",
        "first",
        "quarter",
        "financial",
        "result",
        "operational",
        "highlight",
        "q1",
        "revenue",
        "million",
        "versus",
        "million",
        "current",
        "cash",
        "estimated",
        "sufficient",
        "fund",
        "operation",
        "least",
        "q3",
        "oncomed",
        "pharmaceutical",
        "estimate",
        "operating",
        "cash",
        "burn",
        "approximately",
        "million",
        "considering",
        "potential",
        "milestone",
        "payment",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}